To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Milnacipran is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class.
Milnacipran has been approved and sold in Austria since September 1998 under the brand name Ixel®. Cypress Bioscience bought the exclusive rights for approval and marketing of the drug for any purpose in the US and Canada in 2003 from the manufacturer Pierre Fabre; the approval procedure in both countries is ongoing. In Chile, under the "Ixel" brand name is being sold by Silesia Laboratories.
Milnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitters. The serotonin reuptake inhibition is likely to improve depression, while the norepinephrine reuptake inihibition probably improves chronic pain. Milnacipran exerts no significant actions on postynaptic H1, alpha-1, D1, D2, and muscarinic receptors, as well as on benzodiazepine/opiate binding sites.. In a clinical trial with over 1,000 depressed patients milnacipran showed results comparable to imipramine and superior to SSRIs, but in a different study it was inferior to clomipramine. A meta-analysis of 6 studies involving more than 1,000 patients showed no distinction between milnacipran and SSRIs in efficacy or discontinuation rates, including discontinuation for side effects or lack of efficacy. As with other antidepressants, 1 to 3 weeks may elapse before significant antidepressive action becomes clinically evident.
Milnacipran is well absorbed after oral dosing and has a bioavailability of 85%. Meals do not have an influence on the rapidity and extent of absorption. Peak plasma concentrations are reached 2 hours after oral dosing. The elimination half-life of 8 hours is not increased by liver impairment and old age, but by significant renal disease. Milnacipran is conjugated to the inactive glucuronid and excreted in the urine as unchanged drug and conjugate. Only traces of active metabolites are found. Enzymes of the CYP class do not play a role in the metabolism of Milnacipran.
Indications & Dosage
Milnacipran is used to treat:
The recommended dose for depression is 50mg 2 times daily (after an initial phase of 50mg daily as single dose on days 1 to 4). The dose should be decreased in patients with renal disease. The dosage for the other indications has not been well established so far.
Milnacipran is available in 25mg and 50mg capsules.
After successful treatment of the acute depressive episode, patients should be maintained on Milnacipran for several months (normally 9 months) in order to prevent relapse of depression.
In experimental studies Milnacipran showed useful activity as adjunct in the therapy of Fibromyalgia and Lupus, both conditions with potentially devastating effects. In Fibromyalgia the drug improved pain, mood, and fatigue compared to placebo. In Lupus patients pain was alleviated and a sense of well-being was provided.
On January, 5th., 2006, Forest Pharmaceuticals and Cypress Bioscience agreed to commence a phase III multicenter study encompassing 1,200 patients with Fibromyalgia. On May 22nd, 2007, the phase III study demonstrated statistically significant therapeutic effects of Milnacipran as a treatment of fibromyalgia syndrome. At this time, only initial top-line results are available and further analyses will be completed in the coming weeks.
In April 2007, Progress in Neuro-Psychopharmacology & Biological Psychiatry published an article that presented the case of an adult Attention-deficit hyperactivity disorder (ADHD) patient who found that milnacipren alleviated her symptoms of inattention and hyperactivity. Considering that Milnacipran has fewer side effects than comparable drugs, the authors of the article concluded that it could be studied and developed as an alternative treatment for ADHD .
Side effects include itching, nausea, vertigo, increased anxiety, sweats, shivering, dysuria and testicle pain. Milnacipran does not seem to have a negative impact on sexual functions. The incidence of cardiovascular and anticholinergic side effects was significantly lower compared to TCAs as a controlled study with over 3,300 patients revealed. Cases of hypertension, hypotension and tachycardia have been noted. Elevation of liver enzymes without signs of symptomatic liver disease has been infrequent. Mood swing to mania has also been seen and dictates termination of treatment. In psychotic patients emergence of delirium has been noticed. Milnacipran has a low incidence of sedation but improves sleep (as well duration and quality) in depressed patients. In agitated patients or those with suicidal thoughts additive sedative/anxiolytic treatment is usually indicated.
Administration of milnacipran should be avoided in individuals with the following:
Administration of milnacipran should be done with caution in individuals with the following:
Milnacipran should not be used during pregnancy because it may cross the placenta barrier and no clinical data exists on harmful effects in humans and animal studies. Milnacipran is contraindicated during lactation because it is excreted in the milk, and it is not known if it is harmful to the newborn.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Milnacipran". A list of authors is available in Wikipedia.|